

MD35

MONOGENIC DIABETES TEST

Do patients with monogenic diabetes require insulin therapy?



01 ABOUT MONOGENIC DIABETES

Monogenic diabetes (MD) is a subtype of diabetes caused by a **single gene mutation**. Maturity Onset Diabetes of the Young (MODY) is the main form of monogenic diabetes and is usually diagnosed during **late childhood to adulthood**, accounting for 1-5% of diabetic patients. ¹ Mutations in the gene can reduce insulin production, causing the patient's blood sugar level to be persistently high. Since MODY is a genetic disease, family screening should be performed once a patient is diagnosed to understand the genetic risk to family members. ²

The clinical presentation of MODY usually overlaps with other types of diabetes, making **misdiagnosis common in children with MODY and young patients with diabetes**.

Who should get tested:

 <p>Diabetes patients diagnosed before the age of 25</p>	 <p>Those with a family history of diabetes</p>	 <p>Those with a negative antibodies test result, low to normal C-peptide level</p>
---	--	--

Sources:

1. Kreider, K. E. (2019). The Diagnosis and Management of Atypical Types of Diabetes. The Journal for Nurse Practitioners, 15(2). doi:10.1016/j.nurpra.2018.09.022
2. Hattersley, A. T., & Patel, K. A. (2017). Precision diabetes: Learning from monogenic diabetes. Diabetologia, 60(5), 769-777. doi:10.1007/s00125-017-4226-2

02 DISTINGUISH YOUR MD SUBTYPE

Correct identification of the monogenic diabetes subtype will help doctors provide patients with the most suitable treatment plan. According to a report jointly published by two reputable diabetes organizations, the **American Diabetes Association** and the **European Association for the Study of Diabetes**, genetic testing is the best way to distinguish the different subtypes. ¹


SOME COMMON GENES THAT CAUSE MD ²

Maturity-onset diabetes of the young Neonatal diabetes mellitus Syndrome

● Major clinical phenotype
● Rare clinical phenotype

Gene Mutation	Clinical phenotype(s)	Recommended treatment option
ABCC8	● (Major clinical phenotype)	High-dose oral sulfonylureas
GCK	● (Major clinical phenotype)	No treatment needed for most patients
HNFI1A	● (Major clinical phenotype)	Low-dose oral sulfonylureas
HNF1B	● (Major clinical phenotype)	Optimal treatment not well established
HNF4A	● (Major clinical phenotype)	Low-dose oral sulfonylureas
INS	● (Major clinical phenotype)	Early intensive insulin treatment
KCNJ11	● (Major clinical phenotype)	High-dose oral sulfonylureas

Note: Diabetes is caused by a variety of factors, and the presence of other genetic or non-genetic factors will also affect treatment strategies.



Sources:

1. Chung, W.K., Erion, K., Florez, J.C. et al. (2020). Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 1671-1693. <https://doi.org/10.1007/s00125-020-05181-w>.
2. Riddle, M. C., Phillipson, L. H., Rich, S. S., Carlsson, A., Franks, P. W., Greeley, S., Nolan, J. J., Pearson, E. R., Zeitler, P. S., & Hattersley, A. T. (2020). Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editors' Expert Forum. Diabetes care, 43(12), 3117-3128. <https://doi.org/10.2337/dci20-0065>

03 GEMVCARE TEST



Tests 35 up-to-date genes related to MODY
34 sequenced genes + 1 hotspot (MtA3243G)



Double verification of results



Technical Accuracy - Validated by a local university research team (ranked No. 1 in Endocrinology and Metabolism in Asia)



Quality Assurance - periodical independent verification. GemVCare is a participant of the EMQN# programme



GemVCare has licensed the patent for monogenic diabetes testing

EMQN (European Molecular Genetics Quality Network) is a reputable provider of molecular genetics quality assessment services in Europe.

Sources:

1. Best Global Universities for Endocrinology and Metabolism. U.S. News. <https://www.usnews.com/education/best-global-universities/endocrinology-metabolism?region=asia>. Published 2021.

04 SERVICE FLOW

STEP 1

Collect a specimen of 3ml EDTA anticoagulant blood or saliva*



STEP 2

The specimen will be delivered directly to our testing centre



STEP 3

Your health report will be completed in 50 working days



STEP 4

The report will be explained to you by your healthcare provider



* Please check with your doctor or our service provider for sampling arrangements

05 ABOUT US

GemVCare - committed to helping the public prevent chronic diseases and improving the health of patients.

With professional genetic testing technology for chronic diseases, medical professionals can customize precise treatments and management models according to your personal genetic profile and health conditions so that you can live your best life.

OUR PARTNERS

GemVCare Limited

Unit 628, Biotech Centre 2, 11 Science Park West Ave.,
Hong Kong Science Park, Shatin, N.T., Hong Kong
Tel: (852) 2809 2893
Email: info@gemvcare.com
Website: www.gemvcare.com



GemVCare



GemVCare



General Disclaimer:

Gemomic® Technology is a patented technology adopted by GemVCare® Ltd. ('GemVCare') to assess the risks of diabetes & chronic diseases and its complications.

As the causes of metabolic diseases and its complications are complex, all related tests require professional interpretation. The Gemomic® Technology and any other GemVCare services mentioned in this document (collectively 'services') shall be used for reference purpose only. The service is not medical advice, diagnosis, therapeutic or prophylactic in general or for any particular individual case or patient and should not be treated as a substitute for professional medical diagnosis, advice, therapeutic or prophylactic. Users are reminded to seek professional advice and shall rely or make decisions based on the Service at their own risk.

Neither the author(s) of the reports published for the Services nor GemVCare (including its shareholders, directors, employees and consultants) are liable or have any duty of care for any decisions and/or consequences in relation to the results from the Services.

To the extent permitted by law, GemVCare shall not be liable for any error in or omission from or any misstatement or misrepresentation in the information on this document and GemVCare expressly disclaims and excludes any obligation, responsibility or liability of whatever nature for any loss, damage, costs or expenses (whether direct, indirect or consequential) arising from or in respect of this document, any content, use, misuse or reliance of this document or the information appearing on it or provided through the references. No warranty is given that this document or the information on it will be free from errors or fit for a particular purpose.

The Services is governed, and GemVCare's liability is limited, by separate terms and conditions to this General Disclaimer forms part. All rights in relation to the Service and any publication in relation thereto is fully reserved by GemVCare.